Gonzague Jourdain

Dr. Gonzague Jourdain

French National Research Institute for Sustainable Development (IRD)
+1

Research Focus & Metrics

Academic Career Length

42Years (1985-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2004 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
GJGonzague Jourdain
Gonzague Jourdain
NNNicole Ngo-Giang-Huong
Nicole Ngo-Giang-Huong
SCSophie Le Coeur
Sophie Le Coeur
CBChureeratana Bowonwatanuwong
Chureeratana Bowonwatanuwong
PKPacharee Kantipong
Pacharee Kantipong
PGPerinatal HIV Prevention Trial Group
Perinatal HIV Prevention Trial Group
A single intrapartum dose of nevirapine for the prevention of mother-to-child transmission of human immunodeficiency virus (HIV) leads to the selection of resistance mutations. Whether there are clinically significant consequences in mothers who are subsequently treated with a nevirapine-containing regimen is unknown.

15 July 2004 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
MLMarc Lallemant
Marc Lallemant
GJGonzague Jourdain
Gonzague Jourdain
SCSophie Le Coeur
Sophie Le Coeur
JMJean Yves Mary
Jean Yves Mary
NNNicole Ngo-Giang-Huong
Nicole Ngo-Giang-Huong
VTVallop Thaineua
Vallop Thaineua
Although zidovudine prophylaxis decreases the rate of transmission of the human immunodeficiency virus (HIV) type 1 substantially, a large number of infants still become infected. We hypothesized that the administration, in addition to zidovudine, of a single dose of oral nevirapine to mothers during labor and to neonates would further reduce transmission of HIV.

5 October 2000 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
MLMarc Lallemant
Marc Lallemant
GJGonzague Jourdain
Gonzague Jourdain
SCSophie Le Coeur
Sophie Le Coeur
SKSoyeon Kim
Soyeon Kim
SKSuporn Koetsawang
Suporn Koetsawang
VVVicharn Vithayasai
Vicharn Vithayasai
The optimal duration of zidovudine administration to prevent perinatal transmission of human immunodeficiency virus type 1 (HIV-1) should be determined to facilitate its use in areas where resources are limited.

8 March 2018 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
GJGonzague Jourdain
Gonzague Jourdain
NNNicole Ngo-Giang-Huong
Nicole Ngo-Giang-Huong
LHLinda Harrison
Linda Harrison
LDLuc Decker
Luc Decker
WKWoottichai Khamduang
Woottichai Khamduang
NCNantasak Chotivanich
Nantasak Chotivanich
Pregnant women with an elevated viral load of hepatitis B virus (HBV) have a risk of transmitting infection to their infants, despite the infants’ receiving hepatitis B immune globulin. In this multicenter, double-blind clinical trial performed in Thailand, we randomly assigned hepatitis B e antigen (HBeAg)–positive pregnant women with an alanine aminotransferase level of 60 IU or less per liter to receive tenofovir disoproxil fumarate (TDF) or placebo from 28 weeks of gestation to 2 months post partum. Infants received hepatitis B immune globulin at birth and hepatitis B vaccine at birth and at 1, 2, 4, and 6 months. The primary end point was a hepatitis B surface antigen (HBsAg)–positive status in the infant, confirmed by the HBV DNA level at 6 months of age. We calculated that a sample of 328 women would provide the trial with 90% power to detect a difference of at least 9 percentage points in the transmission rate (expected rate, 3% in the TDF group vs. 12% in the placebo group). From January 2013 to August 2015, we enrolled 331 women; 168 women were randomly assigned to the TDF group and 163 to the placebo group. At enrollment, the median gestational age was 28.3 weeks, and the median HBV DNA level was 8.0 log10 IU per milliliter. Among 322 deliveries (97% of the participants), there were 319 singleton births, two twin pairs, and one stillborn infant. The median time from birth to administration of hepatitis B immune globulin was 1.3 hours, and the median time from birth to administration of hepatitis B vaccine was 1.2 hours. In the primary analysis, none of the 147 infants (0%; 95% confidence interval [CI], 0 to 2) in the TDF group were infected, as compared with 3 of 147 (2%; 95% CI, 0 to 6) in the placebo group (P=0.12). The rate of adverse events did not differ significantly between groups. The incidence of a maternal alanine aminotransferase level of more than 300 IU per liter after discontinuation of the trial regimen was 6% in the TDF group and 3% in the placebo group (P=0.29). In a setting in which the rate of mother-to-child HBV transmission was low with the administration of hepatitis B immune globulin and hepatitis B vaccine in infants born to HBeAg-positive mothers, the additional maternal use of TDF did not result in a significantly lower rate of transmission. (Funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development; ClinicalTrials.gov number, NCT01745822.)

12 October 2020 in Nature Reviews Gastroenterology & Hepatology
Verified
Journal Article
Closed access
PDF file
NTNorah A. Terrault
Norah A. Terrault
MLMiriam T. Miriam Levy
Miriam T. Miriam Levy
KCKa Wang Cheung
Ka Wang Cheung
GJGonzague Jourdain
Gonzague Jourdain

1 December 2007 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
GJGonzague Jourdain
Gonzague Jourdain
JMJean‐Yves Mary
Jean‐Yves Mary
SCSophie Le Coeur
Sophie Le Coeur
NNNicole Ngo-Giang-Huong
Nicole Ngo-Giang-Huong
PYPraparb Yuthavisuthi
Praparb Yuthavisuthi
MLMarc Lallemant
Marc Lallemant
Background. The identification of risk factors for in utero and intrapartum transmission of human immunodeficiency virus type 1 (HIV-1) is crucial to the design and understanding of preventive interventions.